Responses of Swiss-Webster mice to repeated plus-maze experience: Further evidence for a qualitative shift in emotional state?

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 2, 1998, Pages 473-488

  Holmes, A ^a   Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anxiety; Between trial; Factor analysis; Mice; Plus maze; Prior experience; Qualitative change; Within trial

Indexed keywords

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; EMOTION; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; EMOTIONS; EXPLORATORY BEHAVIOR; MALE; MICE;

EID: 0032101192     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00008-2     Document Type: Article

References (53)

1. Adamec R.E., Shallow T. Lasting effects on rodent anxiety of a single exposure to a cat. Physiol. Behav. 54:1993;101-109.
2. Almeida S.S., Garcia R.A., DeOliveira L.M. Effects of early protein malnutrition and repeated testing upon locomotor and exploratory behaviors in the elevated plus-maze. Physiol. Behav. 54:1993;749-752.
3. Belzung C., LePape G. Comparison of different behavioural test situations used in psychopharmacology for the measurement of anxiety. Physiol. Behav. 56:1994;623-628.
4. Blanchard R.J., Parmigiani S., Agullana R., Weiss S.M., Blanchard D.C. Behaviors of Swiss-Webster and C57/BL/6N sin mice in a fear/defense test battery. Aggress. Behav. 21:1995;21-28.
5. Blanchard R.J., Parmigiani S., Bjornson C., Masuda C., Weiss S.M., Blanchard D.C. Antipredator behavior of Swiss-Webster mice in a visible burrow system. Aggress. Behav. 21:1995;123-136.
6. Cao B.-J., Rodgers R.J. Different behavioural profiles of the R(+)- and S(-)-enantiomers of 8-hydroxy-2-(di-n-propylamino)-tetralin in the murine elevated plus-maze. Behav. Pharmacol. 7:1996;810-819.
7. 1A receptor antagonist, in the murine elevated plus-maze. Psychopharmacology (Berlin). 129:1997;365-371.
8. Chaouloff F., Durand M., Mormede P. Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light tests. Behav. Brain Res. 85:1997;27-35.
9. Child D. The essentials of factor analysis. 2:1994;Cassell, London.
10. Cole J.C., Burroughs G.J., Laverty C.R., Sheriff N.C., Sparham E.A., Rodgers R.J. Anxiolytic-like effects of yohimbine in the murine plus-maze. Strain independence and evidence against α2-adrenoceptor mediation Psychopharmacology (Berlin). 118:1995;425-436.
11. Cruz A.P.M., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49:1994;171-176.
12. Dalvi A., Rodgers R.J. GABAergic influences on plus-maze behavior in mice. Psychopharmacology (Berlin). 128:1996;380-397.
13. Dawson G.R., Crawford S.P., Stanhope K.J., Iversen S.D., Tricklebank M.D. One-trial tolerance to the effects of chlordiazepoxide on the elevated plus-maze may be due to locomotor habituation, not repeated drug exposure. Psychopharmacology (Berlin). 113:1994;570-572.
14. Espejo E.F. Structure of the mouse behaviour on the elevated plus-maze test of anxiety. Behav. Brain Res. 86:1997;105-112.
15. Fernandes C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol. Biochem. Behav. 54:1996;31-40.
16. File S.E. One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology (Berlin). 100:1990;281-282.
17. File S.E. Behavioural detection of anxiolytic action. Elliott J.M., Heal D.J., Marsden C.A. Experimental approaches to anxiety and depression. 1992;25-44 John Wiley & Sons Ltd, London.
18. File S.E. The interplay of learning and anxiety in the elevated plus-maze. Behav. Brain Res. 58:1993;199-202.
19. File S.E., Andrews N., Wu P.Y., Zharkovsky A., Zangrossi H. Modification of chlordiazepoxide's neurochemical effects by handling and plus-maze experience. Eur. J. Pharmacol. 218:1992;9-14.
20. File S.E., Mabbutt P.S., Hitchcott P.K. Characterisation of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology (Berlin). 102:1990;98-101.
21. File S.E., Zangrossi H. "One-trial tolerance" to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology (Berlin). 110:1993;240-244.
22. File S.E., Zangrossi H., Sanders F.L., Mabbutt P.S. Raised corticosterone in the rat after expsoure to the elevated plus-maze. Psychopharmacology (Berlin). 113:1994;543-546.
23. File S.E., Zangrossi H., Viana M., Graeff F.G. Trial 2 in the elevated plus-maze. A different form of fear? Psychopharmacology (Berlin). 111:1993;491-494.
24. Gonzalez L.E., File S.E. A five minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus. J. Neurosci. 17:1997;1505-1511.
25. Griebel G., Moreau J.-L., Jenck F., Martin J.R., Misslin R. Some critical determinants of the behaviour of rats in the elevated plus-maze. Behav. Proc. 29:1993;37-48.
26. Griebel G., Sanger D.J., Perrault G. The use of the rat plus-maze to discriminate nonselective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Psychopharmacology (Berlin). 124:1996;245-254.
27. Griebel G., Sanger D.J., Perrault G. Genetic differences in the mouse defense test battery. Aggress. Behav. 23:1997;19-31.
28. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze exploration model of "fear"-motivated behaviour. Naunyn Schmiedebergs Arch. Pharmacol. 327:1984;1-5.
29. Hogg S. A review of the validity and reliability of the elevated plus-maze as a model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30.
30. Kline P. An easy guide to factor analysis. 1994;Routledge, London.
31. Lee C., Rodgers R.J. Antinociceptive effects of plus-maze exposure. Influence of opiate receptor manipulations Psychopharmacology (Berlin). 102:1990;507-513.
32. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berlin). 102:1987;507-513.
33. McCreary A.C., McBlane J.W., Spooner H.A., Handley S.L. 5-HT system and anxiety. Multiple mechanisms in the elevated plus-maze Pol. J. Pharmacol. 48:1996;1-12.
34. Nutt D.J. The pharmacology of human anxiety. Pharmacol. Ther. 47:1990;233-266.
35. Parmigiani S., Brain P.F., Palanza P. Ethoexperimental analysis of different forms of intraspecific aggression in the house mouse (Mus musculus). Blanchard R.J., Brain P.F., Blanchard D.C., Parmigiani S. Ethoexperimental approaches to the study of behavior. 1989;418-431 Kluwer, Dordrecht.
36. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
37. Ramos A., Berton O., Mormede P., Chaouloff F. A multiple-test study of anxiety-related behaviours in six inbred rat strains. Behav. Brain Res. 85:1997;57-69.
38. Rodgers R.J., Cao B.-J., Dalvi A., Holmes A. Animal models of anxiety. An ethological perspective Braz. J. Med. Biol. Res. 30:1997;289-304.
39. Rodgers R.J., Cole J.C. Influence of social isolation, gender, strain and prior novelty on plus-maze behaviour in mice. Physiol. Behav. 54:1993;729-736.
40. Rodgers R.J., Cole J.C. The elevated plus-maze. Pharmacology, methodology and ethology Cooper S.J., Hendrie C.A. Ethology and psychopharmacology. 1994;9-44 John Wiley & Sons Ltd, Chichester.
41. Rodgers R.J., Cole J.C., Cobain M.R., Daly P., Doran P., Eells J.R., Wallis P. Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze. Profile comparisons with 8-OH-DPAT, CGS12066B, TFMPP and mCPP Behav. Pharmacol. 3:1992;621-634.
42. Rodgers R.J., Cutler M.G., Jackson J.E. Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Pharmacol. Biochem. Behav. 57:1997;127-136.
43. Rodgers R.J., Johnson N.J.T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52:1995;621-624.
44. Rodgers R.J., Johnson N.J.T., Carr J., Hodgson T.P. Resistance of experientially induced changes in murine plus-maze behaviour to altered retest conditions. Behav. Brain Res. 86:1997;71-77.
45. Rodgers R.J., Johnson N.J.T., Cole J.C., Dewar C.V., Kidd G.R., Kimpson P.H. Plus-maze retest profile in mice. Importance of initial stages of Trial 1 and response to posttrial cholinergic receptor blockade Pharmacol. Biochem. Behav. 54:1996;41-50.
46. Rodgers R.J., Lee C., Shepherd J.K. Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology (Berlin). 106:1992;102-110.
47. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology (Berlin). 113:1993;237-242.
48. Shepherd J.K. Preliminary evaluation of an elevated "zero-maze" as a model of anxiety in laboratory rats. J. Psychopharmacol. 6:1992;A56.
49. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., Dourish C.T. Behavioural and pharmacological characterisation of the "elevated zero-maze" as an animal model of anxiety. Psychopharmacology (Berlin). 116:1994;56-64.
50. Stephens D.N., Meldrum B.S., Weidmann R., Schnieder C., Grutzner M. Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity? Psychopharmacology (Berlin). 90:1986;166-169.
51. Tancer M.E., Uhde T.W. Social phobia. A review of pharmacological treatments CNS Drugs. 3:1995;267-278.
52. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44:1993;463-469.
53. Trullas R., Skolnick P. Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology (Berlin). 111:1993;323-331.